Chase Investment Counsel Corp Invests $1.13 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Chase Investment Counsel Corp bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, Holdings Channel reports. The firm bought 54,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,126,000.

Several other large investors also recently made changes to their positions in CPRX. Creative Planning grew its holdings in shares of Catalyst Pharmaceuticals by 26.9% during the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 2,699 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Catalyst Pharmaceuticals by 11.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 1,989 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Catalyst Pharmaceuticals by 48.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company’s stock valued at $3,532,000 after acquiring an additional 60,000 shares during the last quarter. Summit Global Investments boosted its holdings in Catalyst Pharmaceuticals by 2.6% in the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock valued at $1,537,000 after acquiring an additional 1,923 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new position in Catalyst Pharmaceuticals in the third quarter valued at about $534,000. Institutional investors own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Stephens reiterated an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Robert W. Baird started coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $22.89 on Friday. The firm has a market cap of $2.73 billion, a P/E ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80. The stock’s 50-day moving average is $22.21 and its 200-day moving average is $21.40. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.